Chemotherapy Induced Cognitive Impairment

ConditionBreast Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Aberdeen

About this trial

Chemotherapy is toxic and challenges everyone differently. Most chemotherapy side-effects are known and well documented. However, the phenomenon of "chemo fog" also known as "chemobrain" has not been fully investigated and is often based on comments of breast cancer patients attending outpatient clinics during and after their chemotherapy. Changes in thinking ability like lack of concentration, loss of memory and the inability to hold a thought or even a conversation has a significant impact on the lives of breast cancer patients. Without understanding what "chemobrain" is, and what causes it, there is little that doctors can do to help at the moment.

The team proposing this study believe that chemotherapy causes chemicals associated with inflammation to attack parts of the brain that are important for concentration and making new memories. Unfortunately, it is not possible to measure these chemicals directly in the brain, but we believe that a brain scan sensitive to excess iron, a marker of brain inflammation, can help. This project will measure thinking ability, such as memory and concentration, take a blood sample and do a brain scan before, during and after a patient has chemotherapy. We will then look for changes in iron in the brain areas that are important for concentration and memory and compare those to changes in thinking ability and to levels of inflammation chemicals in the blood. This information will be essential to help plan our next step which is to test ways to reduce the effects of "chemobrain".

Eligibility criteria

Qualifiers

Women and men >18 years

Diagnosed with HER2 negative breast cancer

Receiving EC-Taxane or Taxane only based chemotherapy

Able to communicate in English

Disqualifiers

Any patient whose physical condition will preclude them from lying still for the duration of the brain scan.

pre-excisting mental condition/disability

Contraindication to magnetic resonance scanning such as an implantable cardiac device.

Trial design

Treatments tested in this trial

  • No intervention

Treatment groups

50 Participants
are divided into 1 treatment group

Sponsors and collaborators

University of Aberdeen

Lead sponsor

NHS Grampian

Collaborator